Figure 1.
Overall survival rates for patients with metastatic PDAC according to RAS mutation status. (A) OS according to RAS mutation status in cfDNA; (B) OS according to RAS mutation status in tissue; (C) OS according to RAS mutation status in cfDNA of those patients with RAS mutations analyzed in tissue.
